Evidence map›Paper›PMID 40635616›Full record

ArticleTechnology in cancer research & treatment

HER2-Targeted Nanoliposome Therapy Activates Immune Response by Converting Cold to Hot Breast Tumors.

Quan Sun, Ying Zhu, Dongli Zhao, Lili Yang, Siyu Zhang, Changxin Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Quan SunHangzhou Normal University, The Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.ORCID 0009-0004-2273-6817
Ying ZhuDepartment of Clinical Hematology and Transfusion, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou, China.
Dongli ZhaoPathology, Affiliated Hospital of Shaoxing University, Shaoxing, China.
Lili YangDepartment of Medical Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
Siyu ZhangDepartment of Medical Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.
Changxin HuangDepartment of Medical Oncology, Affiliated Hospital of Hangzhou Normal University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

IntroductionHER2-positive breast cancer, accounting for 15%-20% of cases, remains challenging due to therapy resistance and immunosuppressive "cold tumor" microenvironments. Current strategies combining immunotherapy with chemotherapy or radiotherapy often face toxicity limitations. To address this, we developed HER2-targeted nanoliposomes co-delivering viral peptides and the STING agonist diABZI, aiming to convert cold tumors into immunologically active "hot tumors" by enhancing antigen spreading and immune recognition.MethodsViral peptides with high Human Leukocyte Antigen-A2 affinity were selected using NetMHCpan-4.1/4.0 and incorporated into nanoliposomes via thin-film dispersion. Trastuzumab F(ab')

Indexed as

Breast NeoplasmsErb-b2 Receptor Tyrosine KinasesLiposomesNanoparticlesCell Line, TumorFemaleHumansImmunotherapyTumor MicroenvironmentERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesLiposomescold tumorsHER2-Positive breast cancerimmunotherapy resistancenanoliposomesSTING agonists

Identifiers

PMID40635616
PMCPMC12254677

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.